Clinical trialsCompany release
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
NeOnc Technologies says its single-arm, 24-patient study of intranasal NEO100 met its primary endpoint, though the data are not from a locked database and no control arm was used.
NeOnc Technologies (NASDAQ: NTHI) has issued a corporate presentation covering its two brain-tumour candidates: intranasal NEO100 and oral NEO212. The deck, dated 18 November 2026, highlights results from a Phase 2a study of NEO100 in recurrent IDH1-mutant grade III-IV glioma.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗
Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
Can-Fite BioPharma Ltd. (CANF) · Wed 18 Nov 2026